Literature DB >> 8204945

[Prognostic value of a continuous variable and an optimal cutoff point].

C Hill1.   

Abstract

To study the prognostic value of a continuous variable, cathepsin D in breast cancer, for example, it has been suggested to consider all the divisions of the population in two groups obtained by changing the cutoff level for cathepsin D, and to select the division leading to the largest difference in survival between the two groups. This method, called optimized cutoff point is statistically incorrect as currently used, and requires corrections. Moreover, the optimised cutoff point will be different in different groups of patients, and has no interpretation either biologically or statistically. Continuous prognostic factors should be studied by dividing the population in more than two groups, in order to examine the shape of the relation between the factor and survival. The limits used to define the groups should not depend on the observed survival in the groups.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8204945

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  4 in total

1.  Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile.

Authors:  C Ceccarelli; D Santini; P Chieco; M Taffurelli; M Gamberini; S A Pileri; D Marrano
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

2.  Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.

Authors:  I Soubeyran; J Wafflart; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

3.  Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE).

Authors:  J Donadieu; M F Auclerc; A Baruchel; Y Perel; P Bordigoni; J Landman-Parker; T Leblanc; G Cornu; D Sommelet; G Leverger; G Schaison; C Hill
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

4.  pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

Authors:  I Soubeyran; N Quénel; J M Coindre; F Bonichon; M Durand; J Wafflart; L Mauriac
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.